CN108159425A - 用于治疗红斑痤疮的组合物 - Google Patents
用于治疗红斑痤疮的组合物 Download PDFInfo
- Publication number
- CN108159425A CN108159425A CN201810145665.XA CN201810145665A CN108159425A CN 108159425 A CN108159425 A CN 108159425A CN 201810145665 A CN201810145665 A CN 201810145665A CN 108159425 A CN108159425 A CN 108159425A
- Authority
- CN
- China
- Prior art keywords
- composition
- alcohol
- oil
- group
- bpo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 179
- 201000004700 rosacea Diseases 0.000 title claims abstract description 39
- 241001303601 Rosacea Species 0.000 title claims abstract description 33
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 122
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 103
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 103
- 238000004090 dissolution Methods 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 239000003094 microcapsule Substances 0.000 claims abstract description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000013270 controlled release Methods 0.000 claims abstract description 9
- 238000012377 drug delivery Methods 0.000 claims abstract description 5
- 238000013268 sustained release Methods 0.000 claims abstract description 5
- 239000012730 sustained-release form Substances 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims description 64
- 230000000996 additive effect Effects 0.000 claims description 54
- -1 polyoxyethylene stearate Polymers 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 10
- 239000003906 humectant Substances 0.000 claims description 9
- 150000002191 fatty alcohols Chemical class 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 229940075529 glyceryl stearate Drugs 0.000 claims description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002270 dispersing agent Substances 0.000 claims description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 239000004584 polyacrylic acid Substances 0.000 claims description 6
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 229940086555 cyclomethicone Drugs 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 4
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 claims description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 4
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 4
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 claims description 4
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 4
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 claims description 4
- 235000019364 tetracycline Nutrition 0.000 claims description 4
- 150000003522 tetracyclines Chemical class 0.000 claims description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229960000735 docosanol Drugs 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 235000004626 essential fatty acids Nutrition 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 229940055577 oleyl alcohol Drugs 0.000 claims description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 150000003408 sphingolipids Chemical class 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002666 1-octacosanol Drugs 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- DKGXIVRSAKPDHF-UHFFFAOYSA-N 6-chloro-3-methyl-1-phenylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=C(Cl)N1C1=CC=CC=C1 DKGXIVRSAKPDHF-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 239000005662 Paraffin oil Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920002396 Polyurea Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000001914 calming effect Effects 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 229940074045 glyceryl distearate Drugs 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229940083037 simethicone Drugs 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims 1
- 229910000271 hectorite Inorganic materials 0.000 claims 1
- 229940043348 myristyl alcohol Drugs 0.000 claims 1
- PKBSGDQYUYBUDY-UHFFFAOYSA-N nonacosyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCO PKBSGDQYUYBUDY-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000002540 palm oil Substances 0.000 claims 1
- 239000003009 skin protective agent Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 abstract description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 59
- 150000004706 metal oxides Chemical class 0.000 description 53
- 239000002245 particle Substances 0.000 description 46
- 238000000034 method Methods 0.000 description 41
- 238000000576 coating method Methods 0.000 description 37
- 239000011248 coating agent Substances 0.000 description 33
- 239000000499 gel Substances 0.000 description 32
- 125000002091 cationic group Chemical group 0.000 description 30
- 239000006185 dispersion Substances 0.000 description 27
- 239000000839 emulsion Substances 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- 239000000725 suspension Substances 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012736 aqueous medium Substances 0.000 description 21
- 230000008569 process Effects 0.000 description 20
- 239000013618 particulate matter Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- 239000011162 core material Substances 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000007900 aqueous suspension Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 239000003093 cationic surfactant Substances 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000000129 anionic group Chemical group 0.000 description 6
- 229920006317 cationic polymer Polymers 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 206010037888 Rash pustular Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 239000003945 anionic surfactant Substances 0.000 description 5
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 206010033733 Papule Diseases 0.000 description 4
- 229920000289 Polyquaternium Polymers 0.000 description 4
- 239000004115 Sodium Silicate Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 4
- 229910052911 sodium silicate Inorganic materials 0.000 description 4
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 229960002788 cetrimonium chloride Drugs 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 1
- IKYKEVDKGZYRMQ-IUQGRGSQSA-N 9,12,15-Octadecatrien-1-ol Chemical compound CC\C=C\C\C=C\C\C=C\CCCCCCCCO IKYKEVDKGZYRMQ-IUQGRGSQSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003046 Application site irritation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 241000193880 Demodex folliculorum Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- BNOODXBBXFZASF-UHFFFAOYSA-N [Na].[S] Chemical compound [Na].[S] BNOODXBBXFZASF-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 239000012868 active agrochemical ingredient Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940008944 clindamycin topical gel Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002342 mephentermine Drugs 0.000 description 1
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003663 metaraminol Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960001094 midodrine Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ALSTYHKOOCGGFT-MDZDMXLPSA-N oleyl alcohol Chemical compound CCCCCCCC\C=C\CCCCCCCCO ALSTYHKOOCGGFT-MDZDMXLPSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- LBIYNOAMNIKVKF-FPLPWBNLSA-N palmitoleyl alcohol Chemical compound CCCCCC\C=C/CCCCCCCCO LBIYNOAMNIKVKF-FPLPWBNLSA-N 0.000 description 1
- LBIYNOAMNIKVKF-UHFFFAOYSA-N palmitoleyl alcohol Natural products CCCCCCC=CCCCCCCCCO LBIYNOAMNIKVKF-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940057402 undecyl alcohol Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810145665.XA CN108159425A (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810145665.XA CN108159425A (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
| PCT/IL2012/050479 WO2014083557A1 (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
| CN201280077293.2A CN104853746B (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280077293.2A Division CN104853746B (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108159425A true CN108159425A (zh) | 2018-06-15 |
Family
ID=47428789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810145665.XA Pending CN108159425A (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
| CN201280077293.2A Active CN104853746B (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280077293.2A Active CN104853746B (zh) | 2012-11-27 | 2012-11-27 | 用于治疗红斑痤疮的组合物 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2925296B1 (https=) |
| JP (1) | JP6423355B2 (https=) |
| CN (2) | CN108159425A (https=) |
| CA (2) | CA3051403C (https=) |
| ES (1) | ES2861431T3 (https=) |
| MX (1) | MX376183B (https=) |
| WO (1) | WO2014083557A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017068673A1 (ja) * | 2015-10-21 | 2017-04-27 | マルホ株式会社 | 皮膚用の医薬組成物 |
| EP3426706A1 (en) | 2016-03-08 | 2019-01-16 | Living Proof, Inc. | Long lasting cosmetic compositions |
| CA3069359C (en) * | 2017-07-12 | 2023-01-10 | Sol-Gel Technologies Ltd. | Compositions comprising encapsulated tretinoin |
| EP3681920B1 (en) | 2017-09-13 | 2025-06-25 | Living Proof, Inc. | Long lasting cosmetic compositions |
| CA3074845A1 (en) | 2017-09-13 | 2019-03-21 | Living Proof, Inc. | Color protectant compositions |
| AU2018370210B2 (en) | 2017-11-20 | 2024-09-26 | Living Proof, Inc. | Properties for achieving long-lasting cosmetic performance |
| EP3784711A1 (en) | 2018-04-27 | 2021-03-03 | Living Proof, Inc. | Long lasting cosmetic compositions |
| EP3586849A1 (en) * | 2018-06-29 | 2020-01-01 | Aprofol AG | Folate preparations |
| JP6811213B2 (ja) * | 2018-07-03 | 2021-01-13 | ソル − ゲル テクノロジーズ リミテッド | 酒さの治療のための組成物 |
| WO2020170029A2 (en) * | 2019-02-19 | 2020-08-27 | Sol-Gel Technologies Ltd. | Method for first-line treatment of rosacea |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008093346A2 (en) * | 2007-02-01 | 2008-08-07 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising a peroxide and retinoid |
| CN101631594A (zh) * | 2006-12-21 | 2010-01-20 | 盖尔德马研究及发展公司 | 包含至少一种维甲酸类和过氧化苯甲酰的乳液 |
| US20100143285A1 (en) * | 2006-11-28 | 2010-06-10 | Galderma Research & Development, Biot, France. | Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer |
| CN101754677A (zh) * | 2007-02-01 | 2010-06-23 | 索尔-格尔科技有限公司 | 制备包含金属氧化物涂层的颗粒的方法和具有金属氧化物涂层的颗粒 |
| CN101969923A (zh) * | 2007-11-30 | 2011-02-09 | 盖尔德马研究及发展公司 | 含有至少一种萘甲酸衍生物、过氧化苯甲酰和至少一种成膜剂的组合物、它们的制备方法及其用途 |
| CN102056481A (zh) * | 2008-06-05 | 2011-05-11 | 陶氏制药科学公司 | 包含低浓度的在水和水混溶性有机溶剂中的悬浮液形式的过氧苯甲酰的局部药物制剂 |
| US20120064135A1 (en) * | 2010-09-15 | 2012-03-15 | Norac Pharma | Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof |
| CN102573765A (zh) * | 2009-01-05 | 2012-07-11 | 溶胶凝胶技术公司 | 含有涂覆的活性剂的局部组合物 |
| CN102596186A (zh) * | 2009-12-31 | 2012-07-18 | 索尔-格尔科技有限公司 | 芯稳定的微胶囊、它们的制备方法以及它们的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2366886T1 (es) * | 2000-04-21 | 2011-10-26 | Sol-Gel Technologies Ltd. | Composición que presenta estabilidad de formulación potenciada y administración de ingredientes activos tópicos potenciado. |
| GB0301577D0 (en) * | 2003-01-23 | 2003-02-26 | Edko Pazarlama Tanitim Ltd Sti | Topical pharmaceutical and/or cosmetic dispense systems |
| FR2886850B1 (fr) | 2005-06-10 | 2007-10-05 | Galderma Sa | Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee |
| WO2008057411A1 (en) * | 2006-11-02 | 2008-05-15 | Stiefel Laboratories, Inc. | Kits containing benzoyl peroxide pads and another acne-treating composition, and formulations and methods of use therefor |
| JP2011529392A (ja) * | 2008-07-31 | 2011-12-08 | ゾル−ゲル テクノロジー リミテッド | 活性成分および金属酸化物シェルを含むマイクロカプセル、その製造方法およびその使用 |
| JP5784619B2 (ja) * | 2009-10-21 | 2015-09-24 | ドウ ファーマシューティカル サイエンシーズ、インク． | 過酸化ベンゾイルを含む粉末を湿潤させるための方法 |
-
2012
- 2012-11-27 EP EP12805780.9A patent/EP2925296B1/en active Active
- 2012-11-27 WO PCT/IL2012/050479 patent/WO2014083557A1/en not_active Ceased
- 2012-11-27 MX MX2015005515A patent/MX376183B/es active IP Right Grant
- 2012-11-27 CA CA3051403A patent/CA3051403C/en active Active
- 2012-11-27 CN CN201810145665.XA patent/CN108159425A/zh active Pending
- 2012-11-27 CN CN201280077293.2A patent/CN104853746B/zh active Active
- 2012-11-27 CA CA2889199A patent/CA2889199C/en active Active
- 2012-11-27 ES ES12805780T patent/ES2861431T3/es active Active
- 2012-11-27 JP JP2015543565A patent/JP6423355B2/ja not_active Expired - Fee Related
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100143285A1 (en) * | 2006-11-28 | 2010-06-10 | Galderma Research & Development, Biot, France. | Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer |
| CN101631594A (zh) * | 2006-12-21 | 2010-01-20 | 盖尔德马研究及发展公司 | 包含至少一种维甲酸类和过氧化苯甲酰的乳液 |
| WO2008093346A2 (en) * | 2007-02-01 | 2008-08-07 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising a peroxide and retinoid |
| CN101754677A (zh) * | 2007-02-01 | 2010-06-23 | 索尔-格尔科技有限公司 | 制备包含金属氧化物涂层的颗粒的方法和具有金属氧化物涂层的颗粒 |
| CN101969923A (zh) * | 2007-11-30 | 2011-02-09 | 盖尔德马研究及发展公司 | 含有至少一种萘甲酸衍生物、过氧化苯甲酰和至少一种成膜剂的组合物、它们的制备方法及其用途 |
| CN102056481A (zh) * | 2008-06-05 | 2011-05-11 | 陶氏制药科学公司 | 包含低浓度的在水和水混溶性有机溶剂中的悬浮液形式的过氧苯甲酰的局部药物制剂 |
| CN102573765A (zh) * | 2009-01-05 | 2012-07-11 | 溶胶凝胶技术公司 | 含有涂覆的活性剂的局部组合物 |
| CN102596186A (zh) * | 2009-12-31 | 2012-07-18 | 索尔-格尔科技有限公司 | 芯稳定的微胶囊、它们的制备方法以及它们的用途 |
| US20120064135A1 (en) * | 2010-09-15 | 2012-03-15 | Norac Pharma | Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof |
Non-Patent Citations (4)
| Title |
|---|
| MONTES, L F等: "Topical treatment of acne rosacea with benzoyl peroxide acetone gel", 《CUTIS》 * |
| 于小兵: "5%过氧苯甲酰治疗蠕形螨感染的酒渣鼻34例临床疗效观察", 《临床皮肤科杂志》 * |
| 侯秀芳: "红斑痤疮的局部治疗进展", 《中国疗养医学》 * |
| 刘颖: "李铁男教授治疗红斑痤疮的临床经验总结", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6423355B2 (ja) | 2018-11-14 |
| CA3051403A1 (en) | 2014-06-05 |
| WO2014083557A1 (en) | 2014-06-05 |
| ES2861431T3 (es) | 2021-10-06 |
| CN104853746A (zh) | 2015-08-19 |
| JP2016501205A (ja) | 2016-01-18 |
| CA2889199C (en) | 2020-05-19 |
| MX376183B (es) | 2025-03-07 |
| MX2015005515A (es) | 2015-07-17 |
| EP2925296A1 (en) | 2015-10-07 |
| EP2925296B1 (en) | 2021-01-06 |
| CN104853746B (zh) | 2018-02-23 |
| CA2889199A1 (en) | 2014-06-05 |
| CA3051403C (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200405665A1 (en) | Methods for the treatment of rosacea | |
| CN104853746B (zh) | 用于治疗红斑痤疮的组合物 | |
| EP2109445B1 (en) | Compositions for topical application comprising a peroxide and retinoid | |
| JP2015518031A (ja) | レチノイド含有マイクロカプセル、その調製方法、及び当該レチノイド含有マイクロカプセルを含む医薬組成物 | |
| US11426378B2 (en) | Method for long-term treatment of rosacea | |
| JP6788066B2 (ja) | 過酸化ベンゾイルおよびアダパレンを含む局所投与用組成物 | |
| JP6811213B2 (ja) | 酒さの治療のための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180615 |
|
| RJ01 | Rejection of invention patent application after publication |